DIT will hold a webinar on 20th September about the Advanced Therapies market in Japan.

The Department for International Trade is organising a Life Science Seminar on “Opportunities in the Advanced Therapy Market in Japan”, taking place at 09.30 on Thursday 20th September.

This is a great opportunity for UK companies to learn about the regulatory frameworks and opportunities in the Advanced Therapy market in Japan. This includes cell therapy, gene therapy, tissue engineering and related products.

The webinar will cover the Japanese regulatory environment for advanced therapies, and how to deal with Japanese partners, as well as a Q&A session. For the webinar, DIT Japan will be joined by CJ Partners, a Japan-based consulting agency specialised in advanced therapies.

The cutting-edge medicine market in Japan is estimated to be worth £9.6 billion in 2016 (according to Fuji Keizai, one of Japan’s leading market research firms) and it is expected to grow by over 30% by 2025. Japan’s cutting-edge medicine market consists of advanced drugs (including antibodies, peptide, RNA drugs), advanced therapeutic products (such as regenerative medicine, cell and gene therapy), and advanced diagnostics/systems (including liquid biopsy, companion diagnostic, and microarray blood test). Regenerative medicine is a fast-emerging sector which is gaining a lot of attention in Japan, with Japanese regulation in this area regarded as one of the most advanced in the world.

The webinar is a pre-cursor to the Department for International Trade Life Sciences Visit to Japan and South Korea which shall be happening in December 2018.

For more information and to register for the webinar please click here.

Share this article